Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.

Various epidemiologic studies have shown that obesity is associated with hepatocellular carcinoma. Leptin, the key player in the regulation of energy balance and body weight control, also acts as a growth factor on certain organs in both normal and disease states. It is plausible that leptin acts to promote hepatocellular carcinogenesis directly affecting malignant properties of liver cancer cells. However, a direct role for leptin in hepatocellular carcinoma has not been shown. In this study, we analyzed the role of leptin and the mechanism(s) underlying its action in hepatocellular carcinoma cells, which express both short and long isoforms of leptin receptors. Treatment with leptin resulted in increased proliferation of both HepG2 and Huh7 cells and involves activation of signal transducers and activators of transcription 3 (STAT3), AKT, and extracellular signal-regulated kinase (ERK) signaling pathways. Leptin-induced phosphorylation of ERK and AKT was dependent on Janus-activated kinase (JAK)/STAT activation. Intriguingly, we also found that leptin potently induces invasion of hepatocellular carcinoma cells in Matrigel invasion and electric cell-substrate impedance-sensing assays. Leptin-stimulated invasion was effectively blocked by pharmacologic inhibitors of JAK/STAT and, to a lesser extent, by ERK and phosphatidylinositol 3-kinase (PI3K) inhibition. Importantly, leptin also induced the migration of both HepG2 and Huh7 cells on fibronectin matrix. Inhibition of JAK/STAT, ERK, and PI3K activation using pharmacologic inhibitors effectively blocked leptin-induced migration of HepG2 and Huh7 cells. Taken together, these data indicate that leptin promotes hepatocellular carcinoma growth, invasiveness, and migration and implicate the JAK/STAT pathway as a critical mediator of leptin action. Our findings have potential clinical implications for hepatocellular carcinoma progression in obese patients.

[1]  M. Atkins,et al.  Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma , 2006, Clinical Cancer Research.

[2]  G. Garcı́a-Cardeña,et al.  Biological action of leptin as an angiogenic factor. , 1998, Science.

[3]  E. Abdalla,et al.  Obesity and diabetes as a risk factor for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  J. Olsen,et al.  Obesity and cancer risk: a Danish record-linkage study. , 1994, European journal of cancer.

[5]  J. Hallenbeck.  What's the story--how patients make medical decisions. , 2002, The American journal of medicine.

[6]  Q. Ye,et al.  A decade’s studies on metastasis of hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[7]  J. Ohannesian,et al.  Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. , 1996, The Journal of clinical investigation.

[8]  R. Busse,et al.  Leptin, the product of Ob gene, promotes angiogenesis. , 1998, Circulation research.

[9]  Apoorva D. Srivastava,et al.  Scratching below the Surface: Wound Healing and Alanine Mutagenesis Provide Unique Insights into Interactions between Eristostatin, Platelets and Melanoma Cells , 2006, Pathophysiology of Haemostasis and Thrombosis.

[10]  D. Mcfadden,et al.  Prostate cancer cell proliferation is influenced by leptin. , 2004, The Journal of surgical research.

[11]  J. Sargeant,et al.  Obesity and cancer , 1988, Veterinary Record.

[12]  J. Wegener,et al.  Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. , 2000, Experimental cell research.

[13]  D. Durden,et al.  PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. , 2003, Cancer research.

[14]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[15]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[16]  A. Toker,et al.  Akt signaling and cancer: surviving but not moving on. , 2006, Cancer research.

[17]  Cai Li,et al.  Leptin: a multifunctional hormone , 2000, Cell Research.

[18]  F. Anania,et al.  Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. , 2006, Endocrine-related cancer.

[19]  Jian-Gao Fan,et al.  Obesity, fatty liver and liver cancer. , 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

[20]  J. Flier,et al.  The Role of SOCS-3 in Leptin Signaling and Leptin Resistance* , 1999, The Journal of Biological Chemistry.

[21]  Joachim Wegener,et al.  Real-time impedance assay to follow the invasive activities of metastatic cells in culture. , 2002, BioTechniques.

[22]  F. Anania,et al.  Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Shaomeng Wang,et al.  Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells , 2004, British Journal of Cancer.

[24]  T. Yamane,et al.  Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. , 1984, Gan.

[25]  P. Leung,et al.  Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. , 2005, The Journal of clinical endocrinology and metabolism.

[26]  D. Rose,et al.  Obesity, adipocytokines, and insulin resistance in breast cancer , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[27]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[28]  Ivan Damjanov,et al.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line , 1979, Nature.

[29]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[30]  P. Heinrich,et al.  Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. , 2002, Molecular endocrinology.

[31]  A. Tarnawski,et al.  Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. , 2005, Biochemical and biophysical research communications.

[32]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[34]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[35]  D. Mcfadden,et al.  Leptin is a growth factor in cancer. , 2004, The Journal of surgical research.

[36]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[37]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[38]  J. Flier,et al.  Identification of SOCS-3 as a potential mediator of central leptin resistance. , 1998, Molecular cell.

[39]  T. Funahashi,et al.  Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines · Adipocyte‐derived Bioactive Substances , 1999, Annals of the New York Academy of Sciences.

[40]  S. Caldwell,et al.  Obesity and hepatocellular carcinoma. , 2004, Gastroenterology.

[41]  E. Elinav,et al.  Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. , 2006, Journal of hepatology.

[42]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[43]  Jeffrey Wyckoff,et al.  Cell migration in tumors. , 2005, Current opinion in cell biology.

[44]  L. Tartaglia,et al.  The Leptin Receptor* , 1997, The Journal of Biological Chemistry.

[45]  H. Yoshiji,et al.  Leptin‐mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats , 2006, Hepatology.

[46]  V. Emilsson,et al.  Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues , 1999, FEBS letters.

[47]  C. Chai,et al.  Potential role of leptin expression in hepatocellular carcinoma , 2006, Journal of Clinical Pathology.

[48]  D. Merlin,et al.  Dystroglycan receptor is involved in integrin activation in intestinal epithelia. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[49]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[50]  O. MacDougald,et al.  Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Sebolt-Leopold.  MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. , 2004, Current pharmaceutical design.

[53]  D. Trichopoulos,et al.  Leptin and Body Mass Index in Relation to Endometrial Cancer Risk , 2002, Annals of Nutrition and Metabolism.

[54]  J. Flier,et al.  Evidence for Leptin Binding to Proteins in Serum of Rodents and Humans: Modulation With Obesity , 1996, Diabetes.

[55]  J. Flier,et al.  Divergent Signaling Capacities of the Long and Short Isoforms of the Leptin Receptor* , 1997, The Journal of Biological Chemistry.

[56]  D. Mcfadden,et al.  Differential effects of leptin on cancer in vitro. , 2003, The Journal of surgical research.

[57]  R. Ahima,et al.  Leptin signaling , 2004, Physiology & Behavior.